Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02833753 · ClinicalTrials.gov registry record · Phase 1
Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI
A Phase 1 study of Colorectal Cancer and Peritoneal Carcinomatosis, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT02833753 is a Phase 1 study of Colorectal Cancer and Peritoneal Carcinomatosis that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 14 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02833753, a Phase 1 study of Colorectal Cancer and Peritoneal Carcinomatosis, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I dose escalation study to determine how much chemotherapy can be safely administered into the abdomen while experiencing the fewest possible side effects.
Conditions Studied
Interventions
- DRUG Oxaliplatin
Study Locations (1)
Massachusetts
- UMass Memorial Medical Center - University Campus - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-07 |
| Est. Completion | 2022-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02833753
The ClinicalTrials.gov registry entry for NCT02833753 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Oxaliplatin is the first listed.
NCT02833753 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02833753 about?
NCT02833753 is a clinical study titled "Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI". This is a Phase I dose escalation study to determine how much chemotherapy can be safely administered into the abdomen while experiencing the fewest possible side effects.
What is the current status of trial NCT02833753?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2016-07. Estimated completion is 2022-02.
What conditions does trial NCT02833753 study?
This clinical trial studies the following conditions: Colorectal Cancer, Peritoneal Carcinomatosis, Appendix Cancer.
What interventions are being tested in trial NCT02833753?
The interventions under investigation include: Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT02833753?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02833753 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.